Nurix Therapeutics, Inc. NRIX
23.08
(0.57)
(2.41%)
as of 25 Sep
- Market cap
- $2.5B
- P/E
- 0.0×
Follow NRIX
| Older periods | Aug '25 | Nov '25 | Feb '26 | May '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
9.16 | 17.45 | 24.24 | 52.54 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(13.36) | (21.61) | (24.20) | (20.00) | |
P/B ratio |
2.06 | 2.72 | 3.62 | 4.80 | |
Price to Tangible BV |
2.06 | 2.72 | 3.62 | 4.80 | |
EV/Sales |
4.04 | 10.39 | 16.71 | 40.48 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(1.47) | (3.50) | (4.61) | (5.07) | |
EV/FCF |
(1.40) | (3.31) | (4.41) | (4.89) | |
Quick Ratio |
5.21 | 6.86 | 5.86 | 6.16 | |
Current Ratio |
5.35 | 7.02 | 6.01 | 6.34 | |
Net Debt/EBITDA |
4.96 | 6.68 | 6.09 | 4.91 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.16 | 0.12 | 0.11 | 0.07 | |
Operating CF/Net income |
0.66 | 0.87 | 0.82 | 1.08 | |
Capex/Depreciation |
(0.54) | 0.90 | (0.28) | (0.50) | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
1,090.96% | 611.50% | 1,345.76% | 969.29% | |
Selling, General and Administrative Expense of Revenue |
166.70% | 100.52% | 233.69% | 172.44% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
123.79% | 66.92% | 150.42% | 125.93% | |
Graham Net Nets |
0.38 | 0.31 | 0.23 | 0.17 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(32.60%) | (17.98%) | (19.99%) | (19.84%) | |
Free Cash Flow Yield |
(31.48%) | (17.98%) | (15.62%) | (15.76%) | |
Revenue per Share |
0.09 | 0.16 | 0.06 | 0.08 | |
Operating CF per Share |
(0.68) | (0.78) | (0.65) | (0.87) | |
Capex per Share |
(0.03) | (0.06) | (0.01) | (0.02) | |
Free Cash Flow per Share |
(0.71) | (0.84) | (0.66) | (0.89) | |
Cash per Share |
5.10 | 6.84 | 4.91 | 3.99 | |
Shareholders Equity per Share |
4.42 | 6.22 | 4.37 | 3.62 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
4.42 | 6.22 | 4.37 | 3.62 | |
Free Cash Flow |
(60.10) | (72.96) | (72.96) | (98.51) | |
Working Capital |
358.25 | 520.35 | 462.20 | 384.46 | |
Capital Expenditures |
(2.71) | (5.13) | (1.04) | (1.94) | |
Net Current Asset Value |
290.38 | 457.43 | 399.16 | 323.57 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.34 | 0.38 | 0.17 | 0.21 | |
Net Profit Margin |
(1,094.77%) | (576.13%) | (1,394.34%) | (990.10%) | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Payables |
6.26 | 11.35 | 9.35 | 9.08 | |
Average Assets |
518.04 | 678.74 | 625.59 | 563.55 | |
Average Common Equity |
374.55 | 532.87 | 480.91 | 425.12 |
Columns are period end dates